CSIMarket
 


Viatris Inc   (VTRS)
Other Ticker:  
 

Cumulative Viatris Inc 's Leverage Ratio for Trailing Twelve Months Period

VTRS's Leverage Ratio for Trailing Twelve Months Period and Total Liabilities, Equity growth


Select the Comparisons : Select the Ratio:

VTRS Leverage Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Growth -2.87 % 8.78 % 5.24 % 2.35 % 2.83 %
Y / Y Total Liabilities Growth 2.64 % -5.44 % -18.76 % -21.57 % -15.91 %
Leverage Ratio for Trailing Twelve Months Period 1.28 1.26 1.31 1.4 1.49
Total Ranking # 1361 # 2151 # 2288 # 2457 # 2908
Seq. Equity Growth -1.91 % 0.11 % -0.4 % -0.69 % 9.85 %
Seq. Total Liabilities Growth -2.36 % 9.56 % -1.75 % -2.34 % -10.05 %


Leverage Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Despite debt repayement of -2.36% in IV. Quarter, Leverage Ratio for Trailing Twelve Months Period improved to 1.28, below Viatris Inc 's average Leverage Ratio for Trailing Twelve Months Period.
Leverage Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 140 other companies have achieved lower Leverage Ratio for Trailing Twelve Months Period than Viatris Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Leverage Ratio?
Who are VTRS's Customers?
Leverage Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 141
Sector # 318
S&P 500 # 1352


Leverage Ratio for Trailing Twelve Months Period Statistics
High Average Low
1.71 1.56 1.34
(Jun 30 2021)   (Dec 31 2023)




Companies with similar average Leverage Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Leverage Ratio for Trailing Twelve Months Period
Ironwood Pharmaceuticals inc   3.52 
Immunome Inc  3.52 
Trevena inc   3.51 
Eli Lilly And Company  3.43 
Travere Therapeutics Inc   3.35 
Cv Sciences Inc   3.31 
Ocular Therapeutix Inc   3.21 
Ascendis Pharma A  3.14 
Kala Bio inc   3.10 
Sellas Life Sciences Group Inc   3.06 
Vaccinex Inc   3.01 
Spectrum Pharmaceuticals Inc   2.86 
Blueprint Medicines Corporation  2.74 
Apexigen Inc   2.65 
Aytu Biopharma Inc   2.60 
Celyad Oncology Sa  2.47 
Corbus Pharmaceuticals Holdings Inc   2.37 
Innovation Pharmaceuticals Inc   2.36 
China Pharma Holdings Inc   2.35 
Phibro Animal Health Corporation  2.29 
Pieris Pharmaceuticals Inc   2.21 
Chembio Diagnostics Inc   2.21 
Orgenesis Inc   2.17 
Qualigen Therapeutics Inc   2.16 
G1 Therapeutics Inc   2.15 
Transcode Therapeutics Inc   2.14 
Apellis Pharmaceuticals Inc   2.14 
Bristol myers Squibb Company  2.11 
Petros Pharmaceuticals inc   2.10 
Proqr Therapeutics N v   2.09 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com